90 completed, 16 terminated, 2 active not recruiting, 2 withdrawn. 48 Phase 3, 27 Phase 2, 22 Phase 1, 14 Phase 4, 1 Not applicable.
Follow Baxalta now part of Shire: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ADVATE in People With Hemophilia A in India ADVATE - Hemophilia A | Phase 4 | Completed | Baxalta now part of Shire | 50 | 2022-01-14 | 2024-03-07 |
| A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants HYQVIA - Healthy Volunteers | Phase 1 | Completed | Baxalta now part of Shire | 51 | 2020-10-27 | 2023-12-14 |
| A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) Immune Globulin Intravenous (IGIV), Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) - Primary Immunodeficiency Diseases (PID) | Phase 3 | Completed | Baxalta now part of Shire | 17 | 2020-08-11 | 2024-03-22 |
| A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A ADYNOVI/ADYNOVATE - Hemophilia A | Active not recruiting | Baxalta now part of Shire | 207 | 2020-07-09 | 2026-02-18 | |
| A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects SHP648 - Hemophilia B | Phase 1 / Phase 2 | Terminated | Baxalta now part of Shire | 2 | 2020-05-13 | 2022-05-19 |
| A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) rVWF, rFVIII - Von Willebrand Disease (VWD) | Phase 3 | Completed | Baxalta now part of Shire | 38 | 2019-04-01 | 2025-09-03 |
| FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) FEIBA - Hemophilia A or B With Inhibitors | Phase 3 | Completed | Baxalta now part of Shire | 45 | 2019-02-12 | 2023-02-14 |
| RIXUBIS PMS India (RIXUBIS PMS) RIXUBIS: On-Demand, RIXUBIS: Prophylaxis - Hemophilia B | Phase 4 | Completed | Baxalta now part of Shire | 25 | 2018-12-07 | 2022-08-30 |
| Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN) CUVITRU - Primary Immunodeficiency Diseases (PID) | Completed | Baxalta now part of Shire | 126 | 2018-09-24 | 2021-03-05 | |
| Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP] No intervention - Congenital Thrombotic Thrombocytopenic Purpura | Completed | Baxalta now part of Shire | 41 | 2018-07-12 | 2021-03-17 | |
| A Study of BAX 888 in Male Adults With Severe Hemophilia A BAX 888 - Hemophilia A | Phase 1 / Phase 2 | Completed | Baxalta now part of Shire | 4 | 2018-02-27 | 2025-09-11 |
| A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) Vonicog alfa, Antihemophilic Factor (Recombinant) - Von Willebrand Disease | Phase 3 | Completed | Baxalta now part of Shire | 47 | 2017-11-06 | 2026-05-15 |
| A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) TAK-755, Standard of care - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | Completed | Baxalta now part of Shire | 52 | 2017-10-13 | 2026-02-09 |
| Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects HYQVIA - Primary Immunodeficiency Diseases (PID) | Phase 3 | Completed | Baxalta now part of Shire | 44 | 2017-09-25 | 2023-10-23 |
| Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia Non-treatment, seroprevalence - Hemophilia A, Hemophilia B | Completed | Baxalta now part of Shire | 242 | 2017-06-14 | 2021-10-25 | |
| Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects HYQVIA, KIOVIG, Cuvitru - Primary Immunodeficiency Diseases (PID) | Phase 4 | Completed | Baxalta now part of Shire | 42 | 2017-05-30 | 2023-01-11 |
| A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD GLASSIA, methylprednisolone or equivalent steroid, Albumin - Graft Versus Host Disease | Phase 2 / Phase 3 | Terminated | Baxalta now part of Shire | 1 | 2017-04-26 | 2021-01-13 |
| Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews Qualitative Interview - Participants/ Patients, Qualitative Interview - Investigators and Study Coordinators - Hemophilia B | Completed | Baxalta now part of Shire | 27 | 2017-03-31 | 2021-04-23 | |
| Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea RIXUBIS - Hemophilia B | Completed | Baxalta now part of Shire | 57 | 2017-01-06 | 2021-05-05 | |
| BAX 802 in CHA With Inhibitors Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802) - Hemophilia A | Phase 3 | Terminated | Baxalta now part of Shire | 8 | 2016-12-22 | 2021-10-20 |
Showing 20 of 111. Sign in to see all of them.
Hemophilia A (40) · Hemophilia B (17) · Primary Immunodeficiency Diseases (14) · alpha 1-Antitrypsin Deficiency (8) · von Willebrand Diseases (5) · Factor 8 deficiency, acquired (4) · Protein C Deficiency (3) · Anemia, Sickle Cell (2) · Blood Coagulation Disorders (2) · Coagulation Protein Disorders (2) · Graft vs Host Disease (2) · Hematologic Diseases (2) · Hemorrhagic Disorders (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Purpura, Thrombocytopenic, Idiopathic (2)
Factor VIII (28) · gamma-Globulins (13) · BAX 855 (9) · F8 protein, human (9) · Factor IX (6) · Solutions (6) · alpha 1-Antitrypsin (6) · Protein C (3) · 5-hydroxymethylfurfural (2) · Albumins (2) · Antibodies (2) · Hizentra (2) · Serum Albumin, Human (2) · Standard of Care (2) · anti-inhibitor coagulant complex (2)
United States (75) · United Kingdom (35) · Germany (31) · Spain (26) · Austria (25) · Poland (25) · Canada (23) · Italy (22) · Russia (20) · Bulgaria (19) · Czechia (18) · France (16) · Netherlands (16) · Ukraine (16) · Sweden (15)
PMID 19216617, PMID 34931880, PMID 26157075, PMID 27220317, PMID 30626238, PMID 31268374, PMID 34036490, PMID 36001294, PMID 39228858, PMID 42578463, PMID 21424824, PMID 22212248, PMID 22476554, PMID 22846381, PMID 23665341, PMID 23777763, PMID 23834666, PMID 23910578, PMID 24697870, PMID 25185574, PMID 25495591, PMID 25623166, PMID 25912619, PMID 26239086, PMID 27328112, PMID 27582171, PMID 27613250, PMID 27891721, PMID 28381506, PMID 28912376, PMID 30003118, PMID 31228628, PMID 31778283, PMID 32207164, PMID 32816519, PMID 32866032, PMID 33067633, PMID 33150384, PMID 35443783, PMID 35934726, PMID 36655343, PMID 37465396, PMID 37646148, PMID 38371314, PMID 38692292, PMID 38978354, PMID 39289739, PMID 39523874, PMID 41937917
2015 (8), 2014 (4), 2009 (3), 2016 (3), 2008 (2), 2018 (2), 1ZIAHL006149-01 (1), 2004 (1), 2005 (1), 2017 (1), 2023 (1)